ALIMTA (BioDeep_00001028411)

   


代谢物信息卡片


ALIMTA

化学式: C20H19N5O6-2 (425.13352740000005)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)[O-])C(=O)[O-]
InChI: InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/p-2/t13-/m0/s1

描述信息

D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

ALIMTA



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Xiangying Li, Guan Wang, Xiuye Sun, Yue Feng, Lei Wang, Gangyuan Sun, Hong Qiao. Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer. Cellular and molecular biology (Noisy-le-Grand, France). 2023 Dec; 69(14):155-160. doi: 10.14715/cmb/2023.69.14.25. [PMID: 38279452]
  • Jin Tian, Lin Long, Jianhua Zang, Wei Liu, Peng Liu, Lili Zhao, Xin Liang, Jun Xiao. Effect of hyperthermia on intestinal microecology, immune function, and progression-free survival in patients with advanced unresectable lung adenocarcinoma. Scientific reports. 2023 10; 13(1):17223. doi: 10.1038/s41598-023-44350-w. [PMID: 37821661]
  • Xue Hou, Chengzhi Zhou, Guowu Wu, Wen Lin, Zhanhong Xie, Haibo Zhang, Jiqun Yi, Zheng Peng, Lifeng Yin, Chi Ma, Likun Chen. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023 06; 18(6):769-779. doi: 10.1016/j.jtho.2023.01.083. [PMID: 36738928]
  • W Jin, L Feng, X S Hu, Z J Wang, X Z Hao, L Lin. [Efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy as first-line treatment for epidermal growth factor receptor-mutant advanced non-small cell lung cancer]. Zhonghua yi xue za zhi. 2023 Apr; 103(16):1196-1201. doi: 10.3760/cma.j.cn112137-20221110-02364. [PMID: 37087402]
  • Aveek Samanta, Saptadipa Banerjee, Tilak Raj Maity, Jangala Jahnavi, Siraj Datta. Towards establishment of a plant-based model to assess the novel anti-cancerous lead molecule(s): An in silico, in vivo and in vitro assessment of some potential anti-cancerous drugs on Lathyrus sativus L. Protoplasma. 2022 Nov; 259(6):1455-1466. doi: 10.1007/s00709-022-01745-2. [PMID: 35195768]
  • Anik Banik, Sheikh Rashel Ahmed, Emran Hossain Sajib, Anamika Deb, Shiuly Sinha, Kazi Faizul Azim. Identification of potential inhibitory analogs of metastasis tumor antigens (MTAs) using bioactive compounds: revealing therapeutic option to prevent malignancy. Molecular diversity. 2022 Oct; 26(5):2473-2502. doi: 10.1007/s11030-021-10345-w. [PMID: 34743299]
  • Si-Hong Lin, Ao Zhang, Lu-Zhen Li, Liang-Chen Zhao, Le-Xia Wu, Can-Tu Fang. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review. BMC endocrine disorders. 2022 Sep; 22(1):239. doi: 10.1186/s12902-022-01151-y. [PMID: 36153581]
  • Pui Ying Chan, Melissa M Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Amit Arora, Gordon Hay, Victoria M L Cohen, Mandeep S Sagoo, John S Bomalaski, Michael T Sheaff, Peter W Szlosarek. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma. Pigment cell & melanoma research. 2022 07; 35(4):461-470. doi: 10.1111/pcmr.13042. [PMID: 35466524]
  • Xiaonan Li, Gang Xing, Xinxin Guo, Yang Wang, Zixia Hu, Maosheng Cheng, Ying Peng, Jiang Zheng. Identification of Metoprolol Tartrate-Derived Reactive Metabolites Possibly Correlated with Its Cytotoxicity. Chemical research in toxicology. 2022 Jun; 35(6):1059-1069. doi: 10.1021/acs.chemrestox.2c00052. [PMID: 35575346]
  • Shekar Shobana, Mahendran Kavitha, Narasimhan Srinivasan. Efficacy of Platelet Rich Plasma and Platelet Rich Fibrin for Direct Pulp Capping in Adult Patients with Carious Pulp Exposure- A Randomised Controlled Trial. European endodontic journal. 2022 Jun; 7(2):114-121. doi: 10.14744/eej.2021.04834. [PMID: 35786576]
  • Shanmugavel Senthilkumar, K K Vinod, Selvaraj Parthiban, Prathima Thirugnanasambandam, Thalambedu Lakshmi Pathy, Nandita Banerjee, Thelakat Sasikumar Sarath Padmanabhan, P Govindaraj. Identification of potential MTAs and candidate genes for juice quality- and yield-related traits in Saccharum clones: a genome-wide association and comparative genomic study. Molecular genetics and genomics : MGG. 2022 May; 297(3):635-654. doi: 10.1007/s00438-022-01870-w. [PMID: 35257240]
  • Jinxiang Yu, Qianyun Zhang, Jie Li, Zhaohui Si, Yuanyuan Guo, Xin Xu, Kanjin Wu. Sequential administration of pemetrexed and cisplatin reprograms tumor immune microenvironment and potentiates PD-1/PD-L1 treatment in a lung cancer model. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2022 03; 70(3):792-799. doi: 10.1136/jim-2021-002159. [PMID: 34872935]
  • Eleonora W J van Ewijk-Beneken Kolmer, Marga J A Teulen, Rene J Boosman, Nikki de Rouw, Jacobus A Burgers, Rob Ter Heine. Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies. Biomedical chromatography : BMC. 2022 Feb; 36(2):e5277. doi: 10.1002/bmc.5277. [PMID: 34741344]
  • Emmanuele S Albuquerque, Larissa dS Pinto, Valfrido LdM Neto, Thiago S Fragoso. Medication adherence in systemic lupus erythematosus during Brazilian COVID-19 pandemic. Lupus. 2022 Feb; 31(2):221-227. doi: 10.1177/09612033221074177. [PMID: 35077262]
  • Quan Chen, Bingbing Wu, Pengfei Ge, Peng Zhang, Xia Chen. Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway. Disease markers. 2022; 2022(?):5614939. doi: 10.1155/2022/5614939. [PMID: 35789603]
  • Jing Xiao, Shishu Wang, Bing Xu, Lisha Yu, Yan Han. Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study. Journal of healthcare engineering. 2022; 2022(?):8963547. doi: 10.1155/2022/8963547. [PMID: 35392141]
  • Índia Olinta de Azevedo Queiroz, Thiago Machado, Camila Carneiro Alves, Ana Maria Veiga Vasques, Marina Tolomei Sandoval Cury, Bruno Carvalho Vasconcelos, João Eduardo Gomes-Filho, Rodrigo Ricci Vivan, Tiago Braga, Robert Matthew Love, Marco Antonio Hungaro Duarte. Tracing the toxic ions of an endodontic tricalcium silicate-based sealer in local tissues and body organs. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS). 2021 Dec; 68(?):126856. doi: 10.1016/j.jtemb.2021.126856. [PMID: 34560425]
  • René J Boosman, Thomas P C Dorlo, Nikki de Rouw, Jacobus A Burgers, Anne-Marie C Dingemans, Michel M van den Heuvel, Lizza E L Hendriks, Bonne Biesma, Joachim G J V Aerts, Sander Croes, Ron H J Mathijssen, Alwin D R Huitema, Rob Ter Heine. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. International journal of cancer. 2021 10; 149(8):1576-1584. doi: 10.1002/ijc.33721. [PMID: 34181276]
  • Peter W Szlosarek, Akhila G Wimalasingham, Melissa M Phillips, Peter E Hall, Pui Ying Chan, John Conibear, Louise Lim, Sukaina Rashid, Jeremy Steele, Paula Wells, Chiung-Fang Shiu, Chih-Ling Kuo, Xiaoxing Feng, Amanda Johnston, John Bomalaski, Stephen Ellis, Marianne Grantham, Michael Sheaff. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer medicine. 2021 10; 10(19):6642-6652. doi: 10.1002/cam4.4196. [PMID: 34382365]
  • Mateus Machado Delfino, José Leandro de Abreu Jampani, Camila Soares Lopes, Juliane M Guerreiro-Tanomaru, Mário Tanomaru-Filho, Estela Sasso-Cerri, Paulo S Cerri. Comparison of Bio-C Pulpo and MTA Repair HP with White MTA: effect on liver parameters and evaluation of biocompatibility and bioactivity in rats. International endodontic journal. 2021 Sep; 54(9):1597-1613. doi: 10.1111/iej.13567. [PMID: 33999424]
  • Paul Dent, Laurence Booth, Andrew Poklepovic, Daniel Von Hoff, Jennifer Martinez, Yong Zhou, John F Hancock. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. Biochemical pharmacology. 2021 08; 190(?):114642. doi: 10.1016/j.bcp.2021.114642. [PMID: 34077739]
  • Edward B Garon, Joachim Aerts, Jong Seok Kim, Catherine E Muehlenbein, Patrick Peterson, Maria Teresa Rizzo, Shirish M Gadgeel. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Lung cancer (Amsterdam, Netherlands). 2021 05; 155(?):53-60. doi: 10.1016/j.lungcan.2021.02.021. [PMID: 33730652]
  • Nikki de Rouw, Rene J Boosman, Alwin D R Huitema, Luuk B Hilbrands, Elin M Svensson, Hieronymus J Derijks, Michel M van den Heuvel, David M Burger, Rob Ter Heine. Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. Clinical pharmacokinetics. 2021 05; 60(5):649-654. doi: 10.1007/s40262-020-00972-1. [PMID: 33420970]
  • Jasmine Giani, Michael B Sawyer, Carole Chambers. Tolerability of pemetrexed and oxaliplatin in the treatment of stage III colon cancer during raltitrexed shortage. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2021 Mar; 27(2):477-479. doi: 10.1177/1078155220934163. [PMID: 32588749]
  • Ailing Xu, Haixia Yan, Tongliang Bu. Therapeutic effect of gefitinib on patients with advanced EGFR-mutation NSCLC. Pakistan journal of pharmaceutical sciences. 2021 Jan; 34(1(Special)):481-486. doi: NULL. [PMID: 34275797]
  • Sara Fuentelsaz-Romero, Celia Barrio-Alonso, Raquel García Campos, Mónica Torres Torresano, Ittai B Muller, Ana Triguero-Martínez, Laura Nuño, Alejandro Villalba, Rosario García-Vicuña, Gerrit Jansen, María-Eugenia Miranda-Carús, Isidoro González-Álvaro, Amaya Puig-Kröger. The Macrophage Reprogramming Ability of Antifolates Reveals Soluble CD14 as a Potential Biomarker for Methotrexate Response in Rheumatoid Arthritis. Frontiers in immunology. 2021; 12(?):776879. doi: 10.3389/fimmu.2021.776879. [PMID: 34804067]
  • Kerem Teralı, Buket Baddal, Hayrettin Ozan Gülcan. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. Journal of molecular graphics & modelling. 2020 11; 100(?):107697. doi: 10.1016/j.jmgm.2020.107697. [PMID: 32739642]
  • Louis Magali, Foucher Pascal, Aho Serge, Boulin Mathieu, Zouak Ayoube, Tinel Claire, Mousson Christiane. Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed. European journal of clinical pharmacology. 2020 Nov; 76(11):1573-1580. doi: 10.1007/s00228-020-02935-8. [PMID: 32564117]
  • Daphne W Dumoulin, Sabine Visser, Robin Cornelissen, Teun van Gelder, Johan Vansteenkiste, Jan von der Thusen, Joachim G J V Aerts. Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 09; 15(9):1472-1483. doi: 10.1016/j.jtho.2020.04.021. [PMID: 32360753]
  • Alfredo Addeo, Luigi Giuseppe Banna, Alex Friedlaender. Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 09; 15(9):1389-1391. doi: 10.1016/j.jtho.2020.05.024. [PMID: 32854908]
  • Bram C Agema, Stijn L W Koolen, Mirjam de With, Nadia van Doorn, Niels Heersche, Esther Oomen-de Hoop, Sabine Visser, Joachim G J V Aerts, Sander Bins, Ron H N van Schaik, Ron H J Mathijssen. Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Genes. 2020 03; 11(4):. doi: 10.3390/genes11040358. [PMID: 32230800]
  • Erik van den Hombergh, Nikki de Rouw, Michel van den Heuvel, Sander Croes, David M Burger, Jeroen Derijks, Nielka P van Erp, Rob Ter Heine. Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma. Therapeutic drug monitoring. 2020 02; 42(1):146-150. doi: 10.1097/ftd.0000000000000672. [PMID: 31348117]
  • Vassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, Suresh S Ramalingam, Angelo Delmonte, Te-Chun Hsia, Janessa Laskin, Sang-We Kim, Yong He, Chun-Ming Tsai, Toyoaki Hida, Makoto Maemondo, Terufumi Kato, Suzanne Jenkins, Sabina Patel, Xiangning Huang, Gianluca Laus, Aleksandra Markovets, Kenneth S Thress, Yi-Long Wu, Tony Mok. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020 01; 126(2):373-380. doi: 10.1002/cncr.32503. [PMID: 31769875]
  • Jin Mo Ku, Se Hyang Hong, Hyo In Kim, Min Jeong Kim, Su-Kyoung Kim, Minkyu Kim, Seok Young Choi, Jeongkoo Park, Hyun Koo Kim, Ji Hye Kim, Hye Sook Seo, Yong Cheol Shin, Seong-Gyu Ko. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2020 Jan; 66(?):153109. doi: 10.1016/j.phymed.2019.153109. [PMID: 31790894]
  • Nikki de Rouw, Sabine Visser, Stijn L W Koolen, Joachim G J V Aerts, Michel M van den Heuvel, Hieronymus J Derijks, David M Burger, Rob Ter Heine. A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Cancer chemotherapy and pharmacology. 2020 01; 85(1):231-235. doi: 10.1007/s00280-019-04006-x. [PMID: 31853639]
  • Milosz Ruszkowski, Bartosz Sekula, Agnieszka Ruszkowska, Roberto Contestabile, Isabel Nogues, Sebastiana Angelaccio, Andrzej Szczepaniak, Zbigniew Dauter. Structural basis of methotrexate and pemetrexed action on serine hydroxymethyltransferases revealed using plant models. Scientific reports. 2019 12; 9(1):19614. doi: 10.1038/s41598-019-56043-4. [PMID: 31873125]
  • David R Spigel, Dianna L Shipley, David M Waterhouse, Suzanne F Jones, Patrick J Ward, Kent C Shih, Brian Hemphill, Michael McCleod, Robert C Whorf, Ray D Page, Joseph Stilwill, Tarek Mekhail, Cindy Jacobs, Howard A Burris, John D Hainsworth. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. The oncologist. 2019 12; 24(12):e1409-e1416. doi: 10.1634/theoncologist.2018-0518. [PMID: 31420467]
  • S Visser, S L W Koolen, P de Bruijn, H N A Belderbos, R Cornelissen, R H J Mathijssen, B H Stricker, J G J V Aerts. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. European journal of cancer (Oxford, England : 1990). 2019 11; 121(?):64-73. doi: 10.1016/j.ejca.2019.08.012. [PMID: 31561135]
  • Mar Collado-González, Sergio López-García, David García-Bernal, Ricardo E Oñate-Sánchez, Christopher J Tomás-Catalá, Jose M Moraleda, Adrián Lozano, Leopoldo Forner, Francisco J Rodríguez-Lozano. Biological effects of acid-eroded MTA Repair HP and ProRoot MTA on human periodontal ligament stem cells. Clinical oral investigations. 2019 Oct; 23(10):3915-3924. doi: 10.1007/s00784-019-02822-2. [PMID: 30684060]
  • Zorawar S Noor, Jonathan W Goldman, William E Lawler, Bijoy Telivala, Fadi Braiteh, Brian A DiCarlo, Kathleen Kennedy, Brad Adams, Xiaoyan Wang, Benjamin Jones, Dennis J Slamon, Edward B Garon. Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2019 09; 135(?):104-109. doi: 10.1016/j.lungcan.2019.05.022. [PMID: 31446981]
  • Meenakshi Srinivasan, Ayyappa Chaturvedula, Michael J Fossler, Anand Patil, Vikram Gota, Kumar Prabhash. Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. Journal of clinical pharmacology. 2019 09; 59(9):1216-1224. doi: 10.1002/jcph.1417. [PMID: 30973978]
  • María Del Carmen Jiménez-Sánchez, Juan José Segura-Egea, Aránzazu Díaz-Cuenca. Higher hydration performance and bioactive response of the new endodontic bioactive cement MTA HP repair compared with ProRoot MTA white and NeoMTA plus. Journal of biomedical materials research. Part B, Applied biomaterials. 2019 08; 107(6):2109-2120. doi: 10.1002/jbm.b.34304. [PMID: 30637928]
  • F J Rodríguez-Lozano, M Collado-González, S López-García, D García-Bernal, J M Moraleda, A Lozano, L Forner, L Murcia, R E Oñate-Sánchez. Evaluation of changes in ion release and biological properties of NeoMTA-Plus and Endocem-MTA exposed to an acidic environment. International endodontic journal. 2019 Aug; 52(8):1196-1209. doi: 10.1111/iej.13107. [PMID: 30828816]
  • Navneet Singh, Milind Baldi, Jyotdeep Kaur, Valliappan Muthu, Kuruswamy T Prasad, Digambar Behera, Amanjit Bal, Nalini Gupta, Rakesh Kapoor. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial. Cancer. 2019 07; 125(13):2203-2212. doi: 10.1002/cncr.32028. [PMID: 30825389]
  • Peter E Hall, Rachel Lewis, Nelofer Syed, Richard Shaffer, Jane Evanson, Stephen Ellis, Matthew Williams, Xiaoxing Feng, Amanda Johnston, Jim A Thomson, Fiona P Harris, Raj Jena, Tomasz Matys, Sarah Jefferies, Kate Smith, Bor-Wen Wu, John S Bomalaski, Timothy Crook, Kevin O'Neill, Dimitris Paraskevopoulos, Ramsay S Khadeir, Michael Sheaff, Simon Pacey, Piers N Plowman, Peter W Szlosarek. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 05; 25(9):2708-2716. doi: 10.1158/1078-0432.ccr-18-3729. [PMID: 30796035]
  • Yuanshan Yao, Yinjie Zhou, Qingwang Hua. Comparing efficacy and safety of regorafenib versus pemetrexed in lung cancer: A preliminary clinical trial evaluating effect of inflammatory biomarkers on disease progression. Pakistan journal of pharmaceutical sciences. 2019 May; 32(3 Special):1293-1299. doi: NULL. [PMID: 31551206]
  • N de Rouw, S Croes, R Posthuma, D E Agterhuis, J J A O Schoenmaekers, H J Derijks, D M Burger, A M Dingemans, R Ter Heine. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Lung cancer (Amsterdam, Netherlands). 2019 04; 130(?):156-158. doi: 10.1016/j.lungcan.2019.01.018. [PMID: 30885337]
  • Bastiaan A Blok, Kristoffer J Jensen, Peter Aaby, Anders Fomsgaard, Reinout van Crevel, Christine S Benn, Mihai G Netea. Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019 Mar; 38(3):449-456. doi: 10.1007/s10096-018-03449-z. [PMID: 30719592]
  • Honglei Jiao, Xinming Zhao, Jiahui Liu, Tuo Ma, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang. In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model. Nuclear medicine and biology. 2019 Jan; 68-69(?):31-39. doi: 10.1016/j.nucmedbio.2018.11.004. [PMID: 30578135]
  • Rudra Pangeni, Saurav Kumar Jha, Ruby Maharjan, Jeong Uk Choi, Kwan-Young Chang, Young Kweon Choi, Youngro Byun, Jin Woo Park. Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative. International journal of nanomedicine. 2019; 14(?):6339-6356. doi: 10.2147/ijn.s209722. [PMID: 31496690]
  • Anna Minchom, Daisy Mak, Ranga Gunapala, David Walder, Rajiv Kumar, Nadia Yousaf, Andrew Hodgkiss, Jaishree Bhosle, Sanjay Popat, Mary E R O'Brien. A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. PloS one. 2019; 14(11):e0225509. doi: 10.1371/journal.pone.0225509. [PMID: 31765437]
  • Xiaohua Gu, Qiang Zhang, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo, Betty Su, Bin Wu. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung cancer (Amsterdam, Netherlands). 2019 01; 127(?):84-89. doi: 10.1016/j.lungcan.2018.11.029. [PMID: 30642557]
  • Ken Uchibori, Miyako Satouchi, Naoko Sueoka-Aragane, Yoshiko Urata, Akemi Sato, Fumio Imamura, Takako Inoue, Motoko Tachihara, Kazuyuki Kobayashi, Nobuyuki Katakami, Chiyuki Kokan, Tomonori Hirashima, Kentaro Iwanaga, Masahide Mori, Keisuke Aoe, Satoshi Morita, Shunichi Negoro. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Lung cancer (Amsterdam, Netherlands). 2018 10; 124(?):65-70. doi: 10.1016/j.lungcan.2018.07.031. [PMID: 30268482]
  • Sabine Visser, Jeannine Huisbrink, Nils E van 't Veer, Jermo J van Toor, Anton J M van Boxem, Nico C van Walree, Bruno H Stricker, Joachim G J V Aerts. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. The European respiratory journal. 2018 10; 52(4):. doi: 10.1183/13993003.00884-2018. [PMID: 30139775]
  • Foyez Mahmud, Ok-Cheol Jeon, Farzana Alam, Ruby Maharjan, Jeong Uk Choi, Jooho Park, Sojung Lee, Jin Woo Park, Dong Soo Lee, Youngro Byun. Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. Journal of controlled release : official journal of the Controlled Release Society. 2018 08; 284(?):160-170. doi: 10.1016/j.jconrel.2018.06.018. [PMID: 29908222]
  • Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, Wenquan Wang, Shawn Fernando, Erin N Ross, Luigi Grasso, Raffit Hassan, J Bradford Kline. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. Cancer biology & therapy. 2018 07; 19(7):622-630. doi: 10.1080/15384047.2018.1449614. [PMID: 29652548]
  • Kartik H Doshi, Bharati Shriyan, Manjunath K Nookala, Sadhana Kannan, Amit Joshi, Vanita Noronha, Vikram Gota, Kumar Prabhash. Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy. Journal of cancer research and therapeutics. 2018 Jul; 14(5):1049-1053. doi: 10.4103/0973-1482.187296. [PMID: 30197346]
  • Cristina Müller, Patrycja Guzik, Klaudia Siwowska, Susan Cohrs, Raffaella M Schmid, Roger Schibli. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates. Molecules (Basel, Switzerland). 2018 06; 23(6):. doi: 10.3390/molecules23061465. [PMID: 29914162]
  • Berrin Küçüktürkmen, Asuman Bozkır. Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells. Drug development and industrial pharmacy. 2018 Feb; 44(2):306-315. doi: 10.1080/03639045.2017.1391835. [PMID: 29023168]
  • Marcel P Stoop, Sabine Visser, Evert van Dijk, Joachim G J V Aerts, Bruno H Stricker, Theo M Luider. High and individually variable enzymatic activity precludes accurate determination of pemetrexed, methotrexate and their polyglutamate metabolite concentrations in plasma. Journal of pharmaceutical and biomedical analysis. 2018 Jan; 148(?):89-92. doi: 10.1016/j.jpba.2017.09.014. [PMID: 28965049]
  • Rudra Pangeni, Jeong Uk Choi, Vijay Kumar Panthi, Youngro Byun, Jin Woo Park. Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. International journal of nanomedicine. 2018; 13(?):3329-3351. doi: 10.2147/ijn.s167958. [PMID: 29922055]
  • Yugo Hamada, Kenji Ikemura, Takuya Iwamoto, Masahiro Okuda. Stereoselective Inhibition of Renal Basolateral Human Organic Anion Transporter 3 by Lansoprazole Enantiomers. Pharmacology. 2018; 101(3-4):176-183. doi: 10.1159/000485920. [PMID: 29353278]
  • Tony S K Mok, Sang-We Kim, Yi-Long Wu, Kazuhiko Nakagawa, Jin-Ji Yang, Myung-Ju Ahn, Jie Wang, James Chih-Hsin Yang, You Lu, Shinji Atagi, Santiago Ponce, Xiaojin Shi, Yuri Rukazenkov, Vincent Haddad, Kenneth S Thress, Jean-Charles Soria. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Dec; 35(36):4027-4034. doi: 10.1200/jco.2017.73.9250. [PMID: 28968167]
  • C J Tomás-Catalá, M Collado-González, D García-Bernal, R E Oñate-Sánchez, L Forner, C Llena, A Lozano, P Castelo-Baz, J M Moraleda, F J Rodríguez-Lozano. Comparative analysis of the biological effects of the endodontic bioactive cements MTA-Angelus, MTA Repair HP and NeoMTA Plus on human dental pulp stem cells. International endodontic journal. 2017 Dec; 50 Suppl 2(?):e63-e72. doi: 10.1111/iej.12859. [PMID: 28891221]
  • Maureen Assayag, Philippe Rouvier, Marion Gauthier, Ghania Costel, Philippe Cluzel, Lucile Mercadal, Gilbert Deray, Corinne Isnard Bagnis. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed. BMC cancer. 2017 Nov; 17(1):770. doi: 10.1186/s12885-017-3705-7. [PMID: 29145816]
  • Kriti Soni, Ali Mujtaba, Kanchan Kohli. Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: Formulation design, characterization, ex vivo, and in vivo assessment. International journal of biological macromolecules. 2017 Oct; 103(?):139-151. doi: 10.1016/j.ijbiomac.2017.05.015. [PMID: 28499946]
  • Yanjun Xu, Zhiyu Huang, Lei Gong, Yun Fan. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity. Anti-cancer drugs. 2017 10; 28(9):1056-1061. doi: 10.1097/cad.0000000000000540. [PMID: 28723866]
  • Linda Sakhri, Julian Pinsolle, Denis Moro-Sibilot, Hélène Pluchart. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report. Journal of medical case reports. 2017 Sep; 11(1):262. doi: 10.1186/s13256-017-1436-7. [PMID: 28915906]
  • Yassir Sbitti, Hafsa Chahdi, Khaoula Slimani, Adil Debbagh, Anouar Mokhlis, Abderrahmane Albouzidi, Fahd Bennani, Hassan Errihani, Mohamed Ichou. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature. Journal of medical case reports. 2017 Jul; 11(1):182. doi: 10.1186/s13256-017-1348-6. [PMID: 28750665]
  • Martin J Edelman, Xiaofei Wang, Lydia Hodgson, Richard T Cheney, Maria Q Baggstrom, Sachdev P Thomas, Ajeet Gajra, Erin Bertino, Karen L Reckamp, Julian Molina, Joan H Schiller, Kisha Mitchell-Richards, Paula N Friedman, Jon Ritter, Ginger Milne, Olwen M Hahn, Thomas E Stinchcombe, Everett E Vokes. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul; 35(19):2184-2192. doi: 10.1200/jco.2016.71.3743. [PMID: 28489511]
  • Krunal Kavathiya, Murari Gurjar, Anand Patil, Madhura Naik, Vanita Noronha, Amit Joshi, Vikram Gota, Kumar Prabhash. A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. Clinical pharmacology in drug development. 2017 May; 6(3):234-239. doi: 10.1002/cpdd.347. [PMID: 28371303]
  • Bjørg Sjøblom, Jūratė Šaltytė Benth, Bjørn H Grønberg, Vickie E Baracos, Michael B Sawyer, Øystein Fløtten, Marianne J Hjermstad, Nina Aass, Marit Jordhøy. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clinical lung cancer. 2017 03; 18(2):e129-e136. doi: 10.1016/j.cllc.2016.09.008. [PMID: 27825639]
  • Shun Lu, Ming Ye, Lieming Ding, Fenlai Tan, Jie Fu, Bin Wu. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget. 2017 Feb; 8(6):9996-10006. doi: 10.18632/oncotarget.14310. [PMID: 28036283]
  • Navneet Singh, Ashutosh N Aggarwal, Jyotdeep Kaur, Digambar Behera. Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy. American journal of clinical oncology. 2017 02; 40(1):75-82. doi: 10.1097/coc.0000000000000111. [PMID: 25089530]
  • Kazuki Sone, Tetsuya Oguri, Makoto Nakao, Yusuke Kagawa, Ryota Kurowaka, Hiromi Furuta, Satoshi Fukuda, Takehiro Uemura, Osamu Takakuwa, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Hidefumi Sato, Hideki Muramatsu, Akio Niimi. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. Anticancer research. 2017 02; 37(2):935-939. doi: 10.21873/anticanres.11402. [PMID: 28179355]
  • F Grossi, E Rijavec, C Genova, G Barletta, F Biello, C Maggioni, G Burrafato, C Sini, M G Dal Bello, K Meyer, J Roder, H Roder, J Grigorieva. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. British journal of cancer. 2017 01; 116(1):36-43. doi: 10.1038/bjc.2016.387. [PMID: 27898657]
  • Kenji Matsuyama. Development of a Prodrug of Levofloxacin to Avoid Chelation with Al3+ and of Pemetrexed Dimedoxomil Esters for Oral Administration. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2017; 137(9):1087-1094. doi: 10.1248/yakushi.17-00095. [PMID: 28867695]
  • Lin Wang, Chuanhao Tang, Bin Xu, Lin Yang, Lili Qu, Liangliang Li, Xiaoyan Li, Weixia Wang, Haifeng Qin, Hongjun Gao, Kun He, Xiaoqing Liu. Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma. PloS one. 2017; 12(6):e0179000. doi: 10.1371/journal.pone.0179000. [PMID: 28594947]
  • O Fiala, P Hosek, M Pesek, J Finek, J Racek, T Buchler, A Poprach, K Hejduk, R Chloupkova, O Sorejs, M Ecksteinova, M Vitovec, K Cizkova, R Kucera, O Topolcan. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma. 2017 ; 64(4):605-610. doi: 10.4149/neo_2017_416. [PMID: 28485168]
  • Berrin Küçüktürkmen, Burcu Devrim, Ongun M Saka, Şükran Yilmaz, Taibe Arsoy, Asuman Bozkir. Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells. Drug development and industrial pharmacy. 2017 Jan; 43(1):12-21. doi: 10.1080/03639045.2016.1200069. [PMID: 27277750]
  • Nasser H Hanna, Rolf Kaiser, Richard N Sullivan, Osvaldo Rudy Aren, Myung-Ju Ahn, Beatrice Tiangco, Isabelle Voccia, Joachim von Pawel, Vladimir Kovcin, Jason Agulnik, Birgit Gaschler-Markefski, José Barrueco, Patricia Sikken, Charles Schloss, Joo-Hang Kim. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung cancer (Amsterdam, Netherlands). 2016 12; 102(?):65-73. doi: 10.1016/j.lungcan.2016.10.011. [PMID: 27987591]
  • Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet. Oncology. 2016 Nov; 17(11):1497-1508. doi: 10.1016/s1470-2045(16)30498-3. [PMID: 27745820]
  • Tomoya Miura, Satoshi Iida, Takahiro Igaki, Hiroyuki Shiobara, Ryou Matsumoto, Katsutaka Mitachi, Teppei Miyakawa, Yoshiaki Ohata, Katsumasa Saitou, Takumi Irie, Shigeru Yamazaki. [Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy. 2016 Nov; 43(12):2106-2108. doi: NULL. [PMID: 28133237]
  • Kenji Ikemura, Yugo Hamada, Chinatsu Kaya, Tomoyuki Enokiya, Yuichi Muraki, Hiroki Nakahara, Hajime Fujimoto, Tetsu Kobayashi, Takuya Iwamoto, Masahiro Okuda. Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. Drug metabolism and disposition: the biological fate of chemicals. 2016 10; 44(10):1543-9. doi: 10.1124/dmd.116.070722. [PMID: 27465369]
  • Enrica Fung, Shuchi Anand, Vivek Bhalla. Pemetrexed-Induced Nephrogenic Diabetes Insipidus. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2016 Oct; 68(4):628-632. doi: 10.1053/j.ajkd.2016.04.016. [PMID: 27241854]
  • Mitsunori Higuchi, Yuki Owada, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Takeo Hasegawa, Hiroyuki Suzuki. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World journal of surgical oncology. 2016 Sep; 14(1):238. doi: 10.1186/s12957-016-0998-y. [PMID: 27595749]
  • Marcel P Stoop, Sabine Visser, Evert van Dijk, Joachim G J V Aerts, Bruno H Stricker, Theo M Luider. A new quantification method for assessing plasma concentrations of pemetrexed and its polyglutamate metabolites. Journal of pharmaceutical and biomedical analysis. 2016 Sep; 128(?):1-8. doi: 10.1016/j.jpba.2016.04.036. [PMID: 27209449]
  • Chen-Yue Qian, Yi Zheng, Ying Wang, Juan Chen, Jun-Yan Liu, Hong-Hao Zhou, Ji-Ye Yin, Zhao-Qian Liu. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chinese journal of cancer. 2016 09; 35(1):85. doi: 10.1186/s40880-016-0145-8. [PMID: 27590272]
  • Kazuhiro Usui, Shunichi Sugawara, Masaru Nishitsuji, Yuka Fujita, Akira Inoue, Atsuto Mouri, Hiroshi Watanabe, Hiroshi Sakai, Ichiro Kinoshita, Yoshihito Ohhara, Makoto Maemondo, Hiroshi Kagamu, Koichi Hagiwara, Kunihiko Kobayashi. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung cancer (Amsterdam, Netherlands). 2016 09; 99(?):131-6. doi: 10.1016/j.lungcan.2016.07.003. [PMID: 27565928]
  • Toshio Inui, Haruka Amitani, Kentaro Kubo, Daisuke Kuchiike, Yoshihiro Uto, Takahito Nishikata, Martin Mette. Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields. Anticancer research. 2016 Jul; 36(7):3767-70. doi: NULL. [PMID: 27354652]
  • Yosuke Ando, Takahiro Hayashi, Moeko Ujita, Sumie Murai, Hideki Ohta, Kaori Ito, Teppei Yamaguchi, Minori Funatsu, Yoshiaki Ikeda, Kazuyoshi Imaizumi, Kenji Kawada, Kimio Yasuda, Shigeki Yamada. Effect of renal function on pemetrexed-induced haematotoxicity. Cancer chemotherapy and pharmacology. 2016 07; 78(1):183-9. doi: 10.1007/s00280-016-3078-7. [PMID: 27286996]
  • Mitra Najmi, Rongbao Zhao, Andras Fiser, I David Goldman. Role of the tryptophan residues in proton-coupled folate transporter (PCFT-SLC46A1) function. American journal of physiology. Cell physiology. 2016 07; 311(1):C150-7. doi: 10.1152/ajpcell.00084.2016. [PMID: 27251438]
  • Clemens C Stoffregen, Elisabeth A Odin, Göran U Carlsson, Göran K Kurlberg, Hillevi G Björkqvist, Maria T Tångefjord, Bengt G Gustavsson. Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation. Anti-cancer drugs. 2016 Jun; 27(5):439-46. doi: 10.1097/cad.0000000000000345. [PMID: 26825869]
  • Wieneke A Buikhuisen, Marion Scharpfenecker, Arjan W Griffioen, Catharina M Korse, Harm van Tinteren, Paul Baas. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 05; 11(5):758-768. doi: 10.1016/j.jtho.2016.01.014. [PMID: 26845191]
  • Sheng-Bin Shi, Meng Wang, Jing Tian, Rui Li, Chun-Xiao Chang, Jie-Lin Qi. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. Translational research : the journal of laboratory and clinical medicine. 2016 Apr; 170(?):1-7. doi: 10.1016/j.trsl.2015.11.006. [PMID: 26687391]
  • Ondrej Fiala, Milos Pesek, Jindrich Finek, Martin Svaton, Ondrej Sorejs, Zbynek Bortlicek, Radek Kucera, Ondrej Topolcan. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. Anticancer research. 2016 Jan; 36(1):461-6. doi: NULL. [PMID: 26722082]
  • Noha Essam Eldin, Amr S Abu Lila, Kazuyoshi Kawazoe, Hanan M Elnahas, Mahmoud A Mahdy, Tatsuhiro Ishida. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016 Jan; 81(?):60-6. doi: 10.1016/j.ejps.2015.09.015. [PMID: 26415830]
  • Hidenori Ando, Sakiko Kobayashi, Amr S Abu Lila, Noha Essam Eldin, Chihiro Kato, Taro Shimizu, Masami Ukawa, Kazuyoshi Kawazoe, Tatsuhiro Ishida. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. Journal of controlled release : official journal of the Controlled Release Society. 2015 Dec; 220(Pt A):29-36. doi: 10.1016/j.jconrel.2015.10.019. [PMID: 26476173]
  • Jing Tian, Ming Shang, Sheng-Bin Shi, Yong Han, Jun Xu. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. Cancer chemotherapy and pharmacology. 2015 Oct; 76(4):829-34. doi: 10.1007/s00280-015-2854-0. [PMID: 26330330]